VXRT 0,96$ (-36%)

10 Mio. $ Equity Offering

https://seekingalpha.com/news/...t-35-percent-pricing-equity-offering

 

Meiner Meinung nach ist Vaxart von einer Zulassung noch weit entfernt. Die Zugänge des Fachpersonals stimmen mich aber für die Zukunft sehr positiv. Ein Durchbruch wäre endlich mal Finanzierung, warten wir mal die weiteren Studienergebnisse ab.
Ist hier halt hochspekulativ, Daumen drücken ist angesagt!
 

hier bald zwei Stellen vor dem Komma, IMO.
 

…The booster data could be huge if the vaccine can protect against the Delta variant. In our view, the recent noravirus data where VXRT demonstrated the ability to boost the immune response in patients who had previously received the VXRT vaccine candidate bodes well for the upcoming booster data in COVID-19.

Importantly, the company has also made progress on the manufacturing front with an announcement expected by year end on the progress. VXRT has the potential to be both a major player and part of the long-term vaccine solution. The stock is a buy under $15 with a target price of $30 per share.

https://finance.yahoo.com/news/...-looks-oral-vaccines-100000588.html  

H.C. Wainwright 23rd Annual Global Investment Conference - September 13-15, 2021

https://twitter.com/vaxart/status/1435343651073372162?s=21  

Vaxart To Present at Upcoming Vaccine Conferences

…Susan Johnson PhD, will present at both ID Week 2021 and the 15th Vaccine Congress. Dr. Johnson will provide an update on the development of Vaxart's COVID-19 oral vaccine candidate.

https://www.prnewswire.com/news-releases/...onferences-301383206.html  

Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial

https://investors.vaxart.com/news-releases/...ii-covid-19-oral-tablet  

https://finance.yahoo.com/news/vaxart-vxrt-sees-hammer-chart-112911742.html?.tsrc=fin-srch

 

New Duke University-led study shows that Vaxart’s oral #COVID19 vaccine candidate reduces airborne transmission of #SARSCoV2 infection in animal model

https://twitter.com/vaxart/status/1446203751853928449?s=21  

New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model

October 7, 2021 at 4:13 PM EDT

Data published in bioRxiv confirmed previous findings suggesting mucosal vaccines could reduce transmission of airborne viruses such as COVID-19 and flu more than injectable vaccines
Study suggests mucosal vaccines may protect not only vaccinated, but also unvaccinated animals

SOUTH SAN FRANCISCO, Calif., Oct. 7, 2021 /PRNewswire/ -- A Duke University-led study published in bioRxiv showed that Vaxart, Inc.'s (NASDAQ: VXRT) investigational oral tablet vaccine reduced the airborne transmission of SARS-CoV-2 virus in an animal model.

These results are consistent with those from Vaxart's Phase II human flu challenge study, which showed that Vaxart's oral tablet vaccine was better at reducing shedding than the injectable flu vaccine comparator.

A limitation of the currently approved injected COVID-19 vaccines is that airborne transmission occurs in people who have received them. The preclinical study also demonstrated that Vaxart's oral vaccine platform induces robust systemic and mucosal responses.

Researchers vaccinated hamsters orally or intranasally with Vaxart's S-only vaccine candidate and then exposed them to significant levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared infectious virus in the nose and lungs quickly. Before clearing the infection, the vaccinated hamsters were exposed to unvaccinated hamsters via aerosol. The mucosally vaccinated hamsters infected fewer hamsters and created less severe clinical symptoms than did unvaccinated hamsters.

"These findings show that our vaccine candidate can reduce transmission of SARS-CoV-2, even when there is infection breakthrough in vaccinated subjects," said Dr. Sean Tucker, the study's lead author and Chief Scientific Officer at Vaxart.

"Existing injected vaccines don't always protect against viral shedding and transmission to other people. A vaccine that reduces shedding and reduces the probability of infection could make a big difference in protecting lives and public health, particularly given the large number of unvaccinated individuals. This study used the same vaccine candidate Vaxart is using in its development of an oral tablet vaccine," added Dr. Tucker.

Earlier this week, Vaxart initiated recruiting for a global Phase II clinical trial of its oral tablet COVID-19 vaccine candidate, which targets the SARS-CoV-2 viral spike (S) protein.

"Vaxart previously published data from a human influenza challenge study that demonstrated our oral flu vaccine candidate inhibited shedding of viral RNA better than injectable vaccines. The data reported provides further evidence that our oral vaccine could offer both an easier, more attractive mode of administration and potentially superior protection against respiratory viruses," said Andrei Floroiu, Vaxart's Chief Executive Officer.

The mucosal surface of the upper respiratory tract is the initial site of SARS-CoV-2 replication and the primary site of infection. Vaccines that induce robust mucosal immune responses may have the greatest impact on reduction of SARS-CoV-2 transmission. Approved COVID-19 vaccines, all of which are administered via intramuscular injection, stimulate systemic immune responses but have minimal effects on mucosal immunity.

https://investors.vaxart.com/news-releases/...s-vaxarts-oral-covid-19  

$7.85 10.72%
Volume: 2.99M

https://www.marketwatch.com/investing/stock/vxrt?mod=over_search  

Was für ein Strohfeuer. Bis Ladenschluss ist das Ding mit ein paar Prozent im Minus wenn es so weitergeht.  

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

https://investors.vaxart.com/news-releases/...orts-third-quarter-2021  

Vaxart Announces Acquisition of Second GMP Manufacturing Facility

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) has entered into an agreement with Kindred Bioscience, Inc. (“KindredBio”) for the purchase of KindredBio’s manufacturing equipment and sublease of its GMP (Good Manufacturing Practices) manufacturing facility in Burlingame, California, giving Vaxart control of its second GMP manufacturing facility…..

…This acquisition gives us greater flexibility to manage our manufacturing needs by allowing Vaxart to exercise more control over our quality control program and the timing of our manufacturing activities,” said Andrei Floroiu, Vaxart’s Chief Executive Officer.

https://investors.vaxart.com/news-releases/...-manufacturing-facility  

Developing the Pill that Moves the Needle

https://investors.vaxart.com/static-files/...8-4d98-910c-f1ae3629789c  

Vaxart COVID booster on track for first half of the year, says Piper Sandler Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $18 price target on Vaxart after her discussion with its management. The analyst contends that the Street does not seem to value IgA immunity, even though 33% of triple-vaccinated patients have been re-infected with the omicron variant. Rahimi adds that Vaxart management was in "high spirits" during the call and believes that topline data for VXA-CoV2-1 Phase 2 Part A booster study is on track for the first half of the year.

Read more at:
https://thefly.com/n.php?id=3440597  

Overweight rating vom 13.01.22

https://stocktwits.com/T_Cell_Tim/message/429380023  

A universal vaccine could be the future of the coronavirus fight

https://www.cnn.com/2022/01/27/health/...xplainer-wellness/index.html  

Zurück über $5.
Der hier die letzten Tage 50k gekauft und am nächsten Tag wieder verkauft hat oder sogar ausgestoppt wurde, beißt sich jetzt wohl in den Hintern.

https://ih.advfn.com/...;width=800&vol=1&height=400&Vol=1  

11.02.22
State Street Corporation
11.187.642 shares
8.91%

https://investors.vaxart.com/static-files/...b-4308-8c12-b389d86d4a3b

07.02.22
BlackRock
8.452.420
6.70%

https://investors.vaxart.com/...s896e7e10-104c-49a5-8cdf-c9fd5b24d2ea  

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

February 24, 2022 at 8:30 AM EST

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19

S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs

Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission

https://investors.vaxart.com/news-releases/...e-produces-strong-cross



Wobei News im Moment doch schon eher zweitrangig sind.  

Company begins 2022 with multiple active programs with data readouts expected this year

Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus studies also expected this year

Ended 2021 with $182.7 million in cash, cash equivalents and marketable securities

https://investors.vaxart.com/news-releases/...ts-fourth-quarter-and-0  

gut? wie geht's nun weiter? Was meint Ihr?  

Wie lange reicht der Cashbestand aus, hierzu ein aktueller SA Artikel:

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

•Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.

•Vaxart's oral vaccine technology is unique and holds great potential with several advantages like easier route of administration, room temperature stability, and greater potential ability to prevent transmission.

•An oral vaccine candidate being developed for norovirus holds potential to target a market worth up to $10 billion in the United States alone.

•An oral vaccine candidate being developed for influenza holds potential to target a market worth up to $5 billion in the United States alone.

•I do much more than just articles at Biotech Analysis Central: Members get access to model portfolios, regular updates, a chat room, and more.


…. That means it expects it has enough cash until at least February of 2023. I believe it can tap into the ATM it has for the time being unless it really needs to raise a substantial amount of cash for another purpose. If it does intend to do another type of cash raise, then I believe it would happen before the end of this year.

https://seekingalpha.com/article/...vid-19-play-oral-vaccine-platform  

16.04.22
Nasal sprays and pills could be 'game-changer' in future fight against Covid-19

...Vaxart, a US-based biotech company, was working on an oral vaccine for norovirus when the pandemic started, and it had already worked out how to protect a vaccine from gastric acids and get it into the gut lining.

This technology was adapted for coronavirus and results of Phase II trials of their oral Covid-19 vaccine are due any day.

Preliminary studies show it activates IgA antibodies in both the nose and the bloodstream, as well as a stronger T-cell response. It also reduces viral shedding and infections.

Vaxart’s Chief Scientific Officer, Dr Sean Tucker, says: “By providing broader immunity we can reduce the potential for new variants.

An oral tablet vaccine could transform how the world is protected from Covid-19 and other infections because they are easy to distribute and administer.”

He adds: “There are big advantages for vaccination programmes because it doesn’t require storage at very cold temperatures and anyone can administer a pill.”

Another potential plus is getting vaccines to people who are frightened of needles. Research has confirmed that despite the risks associated with contracting Covid-19, this is a barrier for one in 10 people in the UK.

https://www.mirror.co.uk/lifestyle/health/...ills-could-game-26726892


 

Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers

Funding and support provided by Bill & Melinda Gates Foundation
Study will focus on determining the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants...

https://finance.yahoo.com/news/...tive-funding-leading-130000709.html